Read twice and referred to the Committee on Finance.
The bill (Alternatives to PAIN Act) amends Medicare Part D to expand access to certain FDA‑approved non‑opioid drugs for acute or postoperative pain. Beginning January 1, 2026, qualifying non‑opioid drugs would be exempt from Part D deductibles, placed on the lowest cost‑sharing tier, and may not be subject to step therapy requiring opioid trials or prior authorization.
Liberals stress addiction prevention and access gains
Relative to its intended legislative type, this bill is a focused substantive policy amendment to Medicare Part D that clearly defines treatment-level changes (deductible exemption, lowest cost-sharing tier placement) and prohibitions on step therapy and prior authorization for a narrowly defined class of non-opioid pain management drugs.
The bill (Alternatives to PAIN Act) amends Medicare Part D to expand access to certain FDA‑approved non‑opioid drugs for acute or postoperative pain.
Beginning January 1, 2026, qualifying non‑opioid drugs would be exempt from Part D deductibles, placed on the lowest cost‑sharing tier, and may not be subject to step therapy requiring opioid trials or prior authorization.
Qualifying drugs must be non‑opioid, FDA‑labeled for acute/postoperative pain, lack a therapeutically equivalent marketed alternative in the U.S., and have a monthly wholesale acquisition cost at or below the Secretary’s specialty‑tier threshold.
Narrow, pragmatic reform with compromise features and public‑health framing increases prospects, but benefit mandates and unknown fiscal effects reduce odds.
Relative to its intended legislative type, this bill is a focused substantive policy amendment to Medicare Part D that clearly defines treatment-level changes (deductible exemption, lowest cost-sharing tier placement) and prohibitions on step therapy and prior authorization for a narrowly defined class of non-opioid pain management drugs. It is drafted as direct statutory amendments and integrates cleanly with existing Part D provisions.
Liberals stress addiction prevention and access gains
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals stress addiction prevention and access gains
Likely supportive overall because the bill increases access to non‑opioid pain treatments and could reduce opioid exposure and addiction risk.
May press for stronger price and equity safeguards, and for coverage of non‑drug pain care.
Possible concerns about industry pricing and ensuring robust evidence for effectiveness.
Generally positive about expanding safe alternatives to opioids and reducing administrative hurdles, but cautious about cost and fiscal effects.
Will want evidence standards, sunset or review provisions, and analyses of impacts on premiums and program costs.
Skeptical because it constrains Part D plans and MA‑PD management tools, mandating coverage tiers and banning step therapy and prior authorization.
Concerned about federal micromanagement, higher premiums, and industry labeling manipulation without state or market flexibility.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, pragmatic reform with compromise features and public‑health framing increases prospects, but benefit mandates and unknown fiscal effects reduce odds.
The bill has not accumulated any surfaced votes yet.
Liberals stress addiction prevention and access gains
Narrow, pragmatic reform with compromise features and public‑health framing increases prospects, but benefit mandates and unknown fiscal ef…
Relative to its intended legislative type, this bill is a focused substantive policy amendment to Medicare Part D that clearly defines treatment-level changes (deductible exemption, lowest cost-sharing tier placement) a…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.